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INTRODUCTION
The last years of neurobiological research have transformed the way we consider mental illnesses. 
We have gone from a deterministic genetic view to a broader vision that includes the involvement 
of non-cerebral systems. This is especially true for major depression (MD). Historically, MD has 
been perceived as a multifactorial disorder correlated to various neurobiological changes like 
neurotransmitter deficits, endocrine disturbances, impaired plasticity, and neural adaptation 
(Benatti et al., 2016). Indeed, the development and progression of depressive disorders has been 
conceived as the disruption of body allostasis, defined as the process of achieving stability of 
physiological and mental processes through dynamic change (Wang et al., 2019). The main player 
in the “allostatic game” is the brain, an organ designed to integrate signals from the periphery that 
anticipate fluctuations, changes, and needs and coordinates allostatic mediators in order to develop 
successful coping mechanisms that ultimately lead to an adaptative strategy and resilience (de Kloet 
et al., 2005).
The establishment and maintenance of these mechanisms requires large amounts of energy from 
the organism. Without energy, or in a partial lack of energy, the biological mechanisms necessary to 
respond appropriately to stimuli may not occur or be established incorrectly or abnormally.
Human and animal studies suggest an intriguing link between our body’s ability to produce 
energy and the brain’s ability to correctly perform the complex cellular and molecular processes 
involved in allostatic processes.
In eukaryotic cells, mitochondria are the powerhouse that produces and distributes energy 
to all other components. Functional or quantitative alterations of the ability of mitochondria to 
adequately supply energy can have important repercussions primarily on cellular processes and 
cascades of serial events (Herst et al., 2017) as well as on the correct functioning of the organism 
including mechanisms of brain plasticity, mood, and behavior in general (Allen et al., 2018). In this 
framework, it is particularly intriguing to think of the mitochondria as an active regulator of many 
of the biological phenomena involved in depression and in the efficacy of or resistance to the most 
widely used pharmacological treatments.
Once the energetic equilibrium is compromised, the body becomes more “vulnerable.” This is 
especially true for stress-related disorders, such as depression. In fact, depression is often associated 
with energetic imbalance leading to profound effects on the disease (Zuccoli et al., 2017). The 
driving questions then are as follows: What happens to the brain in the presence of an energetic 
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imbalance? Does depression or depression-related symptoms 
impact mitochondrial energetic efficiency? Is antidepressant 
efficacy mediated by mitochondrial functionality?
MITOCHONDRIA AND DEPRESSIVE 
DISORDERS
To answer these questions, we need to (1) evaluate the effects of 
mitochondrial functions on depression or on some aspects of 
depression and (2) consider the possibility that the pathology 
itself or some of its neuroendocrine aspects modify mitochondrial 
function. Each of our cells contains a variable number (from a few 
to thousands) of small organelles called mitochondria (Pizzorno, 
2014). These subcellular structures represent the “power plant” 
of cells, being responsible for a massive production of adenosine 
triphosphate (ATP), an indispensable molecule for life (Johannsen 
and Ravussin, 2009) (Figure 1). The activity of mitochondria 
is even more important for the brain, an organ that uses a huge 
quantity of ATP but that is not able to store large amounts of 
energy reserves (e.g. neurons do not store glucose) (Allen et al., 
2018). Therefore, the integrity of mitochondrial activity is key to 
the continuous energy supply to the brain. Increasing evidence 
implicates mitochondrial dysfunction as a key player in the 
development of neuropsychiatric disorders, such as depression 
(Manji et al., 2012). In particular, deficient mitochondrial function 
is involved in impaired neuronal communication and cellular 
resilience, which in turn have been hypothesized to lead to mood 
disorders and psychotic disorders (Quiroz et al., 2008). Preclinical 
studies show that exposure to chronic mild stress, a well-established 
animal model of depression, induces depressive-like symptoms in 
mice and is accompanied by reduced mitochondrial respiratory 
rates and a dissipated mitochondrial membrane potential in the 
hippocampus, cortex, and hypothalamus (Gong et al., 2011). 
These observations support the hypothesis that mood disorders 
could be associated with an abnormal cerebral energy metabolism 
and, thus, strengthen the supposition that depression is caused 
by an impairment in energy in the brain due to mitochondrial 
genetic vulnerability [A3243G mutation, mitochondrial transfer 
RNALeu(UUR)] and environmental mechanisms (Onishi et al., 
1997). Inflammation and oxidative stress exert a central role in the 
pathogenesis of MD (Joseph et al., 2005). Recently, Kageyama et al. 
(2018) showed a correlation between circulating mitochondrial 
DNA (mtDNA) and inflammation, measured as plasma levels 
of four cytokines [granulocyte macrophage colony-stimulating 
factor (GM-CSF), interleukin (IL)-2, IL-4, and IL-6], in MD 
patients. Patients with MD displayed heightened levels of pro-
inflammatory cytokines, such as IL-6, IL-8, and tumor necrosis 
factor-α (TNF-α), while reduced levels of anti-inflammatory 
cytokines, such as transforming growth factor-β1 (TGF-β1), 
along with an increase in TNF-α levels were observed in the 
plasma of depressed patients (Caraci et al., 2018), which may 
significantly contribute to treatment resistance in MD. Therefore, 
a strong neurobiological link between inflammation, oxidative 
stress, and treatment resistance in MD has been hypothesized. 
Also, a poorer response to antidepressant treatment was related 
to higher baseline levels of the major oxidative stress marker 
F2-isoprostane, which in turn was associated with changes in 
oxidative (8-OHdG) and inflammatory (IL-6) markers (Lindqvist 
et al., 2017). Furthermore, patients with MD displayed higher 
levels of circulating cell-free mitochondrial DNA compared 
to healthy controls, while mtDNA copy number, reflecting 
intracellular mtDNA content and bioenergetics, did not differ 
between the groups (Lindqvist et al., 2018).
Levels of ATP are generally lower in the brain tissue of 
depressed patients than in healthy subjects, while in the muscle 
tissue of patients with MD, an enhanced ATP production rate 
and mtDNA were observed as compared to healthy controls 
(Moretti et al., 2003). Moreover, some studies suggest that the 
pharmacodynamics of different classes of antidepressant drugs 
includes a specific and selective influence on mitochondrial 
energy production mechanisms. As a result, these effects may 
play specific roles in the different cellular compartments, which 
is of particular significance when considering presynaptic and 
postsynaptic compartments (Villa et al., 2016; Villa et al., 2017).
In addition, a recent study expanded “the allostatic load model 
of chronic stress,” focusing on glucocorticoid dysregulation, 
introducing the concept of “mitochondrial allostatic load” (Picard 
et al., 2014), characterized by mitochondrial fragmentation, 
reactive oxygen species (ROS) production, mtDNA damage, 
an early event mediating the relationship between primary 
mediators of chronic stress (e.g. increased levels of cortisol, 
catecholamine, and blood glucose), and disease pathways in MD.
When present at low levels, ROS and reactive nitrogen species 
(RNS) represent a fundamental component of living organisms 
and are implicated in many physiological processes. The ability 
of the antioxidant machinery to keep the levels of ROS and 
RNS low, without ever reaching their complete elimination, is 
therefore extremely important (Cheignon et al., 2018). Among the 
producers of different reactive species, mitochondria are the most 
representative source (Cadenas and Davies, 2000). However, the 
brain, due to the presence of high levels of redox-active transition 
metals along with their high metabolic activity, is one of the most 
vulnerable organs to damage of ROS/RNS (Garbarino et al., 2015). 
Zhu et al. estimated that a resting cortical neuron consumes around 
five billion ATP molecules per second (Zhu et al., 2012). Inevitably, 
brain mitochondria produce high quantities of ROS and RNS 
together with ATP, making the brain increasingly vulnerable to 
oxidative damage. When the balance between pro-oxidants and 
antioxidants fails and pro-oxidants are in excess, a phenomenon 
called “oxidative stress” occurs (Birben et al., 2012). Two of the 
most-cited species, nitric oxide (NO) and superoxide anion are 
part of the natural energy metabolism of the cell while also being 
crucially implicated in oxidative stress (de Campos et al., 2015). The 
diffusion-limited reaction between NO and superoxide anion leads 
to the formation of peroxynitrite, the reactive species responsible for 
the damage of important biological macromolecules (Beckman and 
Crow, 1993). Currently, the hypothesis that all the above-mentioned 
species, and oxidative stress in general, play a fundamental role in 
depression is well accepted (Michel et al., 2012).
Preclinical and clinical studies together with various meta-
analysis and systematic reviews strongly underline the role played 
by mitochondrial ROS/RNS metabolism and oxidative stress in 
depression (Liu et al., 2015) (Figure 1). Lipid peroxidation due 
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to ROS generation is particularly relevant as the brain is rich in 
polyunsaturated lipids (Patel, 2016). Levels of malondialdehyde 
(MDA), a well-known marker of oxidative stress involved in 
lipid peroxidation, are increased, while those of antioxidants are 
decreased in depressed patients compared to healthy age- and 
sex-matched controls (Bajpai et al., 2014); levels of MDA were 
significantly higher, and those of ascorbic acid and superoxide 
dismutase (SOD) significantly lower in the serum of depressed 
patients compared to those of controls. Moreover, in depressed 
patients, an association has been observed between plasma MDA 
levels (higher than in healthy subjects) and severity of depressive 
symptoms. Further evidence of oxidative stress and antioxidant 
imbalance in depressed subjects as compared to healthy volunteers 
was provided by altered plasma levels of MDA, NO metabolites, 
antioxidant activity (SOD, vitamins E and C, and uric acid), and total 
antioxidant capacity. Also, the activity of several oxidative stress-
related enzymatic systems has been linked to the pathogenesis of 
depression (Schiavone et al., 2013). For example, Ibi et al. (2017) 
found that mice deficient in NADPH oxidase 1 (Nox1−/Y), which 
displayed a depressive phenotype, showed the involvement of 
NOX1, as well as biochemical and structural changes. Specifically, 
depressive-like behaviors in mice were regulated by the NOX1 
enzyme through redox modification of N-methyl-d-aspartate 
(NMDA) receptor 1. Inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) represent two additional examples of 
enzymes whose activity has been linked to depression. A selective 
iNOS inhibitor (aminoguanidine), in streptozotocin-treated mice 
ameliorated cognitive deficits and depression and reduced the 
activity of iNOS (Zhou et al., 2017). Likewise, the COX-2 inhibitor 
celecoxib has therapeutic effects in patients diagnosed with MD 
suffering from an acute episode and has shown the same effects in 
animal models of depression as well (Muller and Schwarz, 2008). 
As mentioned above, patients with MD are characterized by a 
lowered total antioxidant state and by enhanced mitochondria-
related oxidative stress, which is the reason why antioxidant 
supplementation is increasingly considered as a candidate 
treatment for depression (Figure 1). Converging evidence from 
studies employing both animal models of depression and human 
subjects provides a good perspective for the use of antioxidants in 
combination with antidepressants. Patients with depression had 
significantly lower levels of blood serum levels of vitamins A, C, 
and E in comparison to healthy controls. Dietary supplementation 
of these vitamins increased the blood levels of these antioxidants 
and led to a significant reduction in depression (HAM-D)-related 
symptoms. Moreover, treatment with a supplement of vitamins 
E and C, combined with monoaminergic antidepressant drugs 
for 12  weeks, improved parameters of oxidative stress in MD 
patients (Ghodake et al., 2012). Furthermore, treatment with 
the antioxidant N-acetylcysteine improved depressive symptoms 
and functionality while providing good tolerability (Fernandes 
et al., 2016).
In sum, mitochondria represent an attractive target for drug 
delivery and drug development strategies because of their role in 
cellular energy metabolism and ROS production (Sheu et al., 2006). 
FIGURE 1 | Mitochondrial dysfunction and oxidative stress: the “dangerous cocktail” increasing the risk of developing or triggering depression. (A) Mitochondrial 
physiology. (B) Brain mitochondria produce high quantities of reactive oxygen species (ROS) and reactive nitrogen species (RNS) along with adenosine triphosphate 
(ATP), increasing their own vulnerability (C) and that of the brain (D) to oxidative damage. When the ability of the antioxidant machinery to balance ROS/RNS 
production (E) fails, oxidative stress develops (F). Both oxidative stress and malfunctioning mitochondria (G) represent two risk factors for the development of major 
depression. AO, antioxidants; PO, pro-oxidants.
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During the last decade, a range of strategies have been developed 
with the aim to target antioxidants to mitochondria. Many 
mitochondrially targeted antioxidants exert protective activities. 
Data from a series of in vitro systems suggest that one of them, 
MitoQ (a triphenylphosphonium-based mixture of ubiquinol 
and ubiquinone), was active in both in vitro and in vivo models 
of cardiac ischemia–reperfusion injury, which is associated with 
mitochondrial oxidative damage (Sheu et al., 2006).
Also, several studies have used antioxidant molecules such 
as N-acetylcysteine and curcumin, which target mitochondrial 
monoamine oxidase A, in the treatment of MD (www.clinicaltrials.
gov). Among the emerging natural antioxidants for the treatment of 
MD, carnosine represents one of the most promising (Caruso et al., 
2019b) because of its ability to counteract oxidative stress (Fresta 
et al., 2018; Caruso et al., 2019c), modulate energy metabolism 
and protect brain mitochondria (Caruso et al., 2019a), rescue 
mitochondrial dysfunctions (Corona et al., 2011), and interact with 
cells of the immune system (Fresta et al., 2017). In addition, dietary 
supplementation with carnosine suppressed the effects of chronic 
stress in animals and improved behavior, cognition, and overall 
well-being in human subjects (Hipkiss, 2015). As already postulated 
by Hipkiss some years ago, the therapeutic potential of carnosine in 
the treatment of stress-related and depressive disorders should be 
investigated intensely in future longitudinal studies.
CONCLUSION AND FUTURE DIRECTIONS
Overall, the data suggest an intriguing link between mitochondrial 
function and depression that warrants further investigation. 
First, mitochondria could be considered an important aid in the 
early diagnosis of MD and contribute to the differentiation of 
disorders with overlapping symptoms. Similarly, specific forms 
of mitochondrial dysfunction could be used as biomarkers in 
the evaluation of the underlying causes of the disease. Lastly, 
mitochondrial function may represent a promising new target 
for new antidepressant drugs and the development of customized 
therapy. Energy, behavior, and therapy constitute a triad of great 
scientific and health-related interest. To obtain more accurate 
diagnoses and more effective targeted therapies, it is necessary 
to invest our energy and resources to better comprehend the 
role of the what, why, where, and who of energy production, 
and therefore of mitochondria, and the mechanisms that control 
normal and pathological human behavior.
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